{"id":403013,"date":"2020-12-18T14:08:45","date_gmt":"2020-12-18T19:08:45","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=403013"},"modified":"2020-12-18T14:08:45","modified_gmt":"2020-12-18T19:08:45","slug":"tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/","title":{"rendered":"Tauriga Sciences Inc. Enters into Master Services Agreement with CSTI to Resume the Clinical Development of its Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"start\">\n        \n      <\/p>\n<p align=\"start\">The Company\u2019s Proposed Pharma Grade Version of Tauri-Gum\u2122 is Being Developed Specifically to Target: Patients Subjected to Ongoing Chemotherapy Treatment (the \u201cIndication\u201d)<\/p>\n<p align=\"start\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xI5x73pFJDSNcil6B4QZsQ3P3muKVuk-AIlfDETn_tck2GolnwM9kn5luwFVLijvbVAKJspYWUufWipAeRB2EZk2n5jvSsPNAzJBRg-eSBcbbzuAHaefLhE5hU_4ho1FJ7GGWRoQA5VDzqus8QLCKzUmerNt4CqDbSyUQQqrbXE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n          <u>NEW YORK, NY, Dec.  18, 2020  (GLOBE NEWSWIRE) &#8212; via NewMediaWire<\/u><br \/>\n        <\/a>&#8212; Tauriga Sciences, Inc. (OTCQB:\u00a0TAUG) (\u201cTauriga\u201d or the \u201cCompany\u201d), a revenue generating, diversified life sciences company, with a proprietary line of functional \u201csupplement\u201d chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnologies initiatives, today announced that it has entered into a Master Services Agreement (the \u201cAgreement\u201d) with North Carolina based Clinical Strategies &amp; Tactics, Inc. (\u201cCSTI\u201d) to resume the clinical development of its proposed \u201cAnti-Nausea\u201d pharmaceutical grade version of Tauri-Gum\u2122.\u00a0CSTI will largely be focusing its efforts on the following: Pharmaceutical Development Strategy (\u201cI.\u201d), Commercialization Strategy (\u201cII.\u201d), and Funding Strategy (\u201cIII.\u201d).\u00a0\u00a0The Company will be working closely with CSTI\u2019s Founder &amp; CEO, JoAnn C. Giannone (\u201cMs. Giannone\u201d), who has over 25 years\u2019 experience effectively leading companies through the drug and medical device development process (Prior to founding CSTI, Ms. Giannone held leadership positions with Johnson &amp; Johnson and Pharmacia).\u00a0\u00a0The Company intends to fund the entirety of this Agreement, before the end of Calendar 2020.<\/p>\n<p align=\"start\">&#8212;<\/p>\n<p align=\"start\">I.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Pharmaceutical Development Strategy<\/p>\n<ul>\n<li>Clinical and Non-Clinical safety and efficacy strategy\/studied (e.g., purpose, type, estimated sample size, treatment duration, etc.)<\/li>\n<li>Product development and manufacturing strategy (e.g., physical product formulation, scale up, testing, packaging, and analytical testing to meet stage-appropriate regulatory requirements)<\/li>\n<li>Regulatory submission strategy with defined regulatory milestones (e.g., pre-IND, IND, NDA, etc. and any special designations)<\/li>\n<li>Overall development costs and funding needs by milestone<\/li>\n<li>Overall development timeline<\/li>\n<li>Elements of the development program that should be prioritized for development<\/li>\n<\/ul>\n<p align=\"start\">II.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Commercialization Strategy<\/p>\n<ul>\n<li>Market Assessment<\/li>\n<li>Competitive Analysis<\/li>\n<li>Product Differentiation &amp; Market Advantage<\/li>\n<li>Target Product Profile (\u201cTPP\u201d)<\/li>\n<li>Market Research<\/li>\n<li>Pricing<\/li>\n<li>Reimbursement<\/li>\n<li>Draft Forecast<\/li>\n<\/ul>\n<p align=\"start\">III.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Funding Strategy<\/p>\n<ul>\n<li>Non-Dilutive Options<\/li>\n<li>Commercial Partners, Venture Funds, Universities, Philanthropic Opportunities, Patient Advocacy Groups, etc.<\/li>\n<\/ul>\n<p align=\"start\">&#8212;<\/p>\n<p align=\"start\">The delivery system for this proposed Pharmaceutical version is a modified version (substantially higher concentration of CBD) of the existing \u201cTauri-Gum\u2122\u201d chewing gum formulation based on continued research and development.\u00a0<\/p>\n<p align=\"start\">On March 18, 2020 the Company announced that it had filed a Provisional U.S. Patent covering its Pharmaceutical grade version of Tauri-Gum\u2122.\u00a0This patent application, filed with the United States Patent &amp; Trademark Office (\u201cU.S.P.T.O.\u201d), is titled: \u201cMEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT.\u201d<br \/>\u00a0\u00a0\u00a0<br \/>U.S. Provisional Patent Application No. 62\/990,709<\/p>\n<p align=\"start\">Below &#8211; CSTI Corporate Website:<\/p>\n<p align=\"start\">Link:\u00a0\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZD3JtLFc3CwWrPAAqldlDVQBSnGBbMMVltMfQMed0ZphXTBXP6ss3c7HFQMnwUPLja5vqmK5BUTkXj2fwaEnoAa52jYMpeK_o0wBM6tOAzMltQdvGMWgDIu2jpyM1Rk7\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>http:\/\/www.csandti.com\/index.html<\/u><\/a><\/p>\n<p align=\"start\">\n        <b>ABOUT TAURIGA SCIENCES INC.<\/b>\n      <\/p>\n<p align=\"start\">Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.\u00a0\u00a0The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (\u201cCBD\u201d) and Cannabigerol (\u201cCBG\u201d) Edibles market segment.\u00a0\u00a0The main product line, branded as Tauri-Gum\u2122, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum\u2122 Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum\u2122 Flavors: Peach-Lemon, Black Currant) &amp; (Vitamin C + Zinc \u201cImmune Booster\u201d Tauri-Gum\u2122 Flavor: Pear Bellini).\u00a0\u00a0The Company\u2019s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at\u00a0http:\/\/www.tauriga.com<\/p>\n<p align=\"start\">Complementary to the Company\u2019s retail business, are its two ongoing biotechnology initiatives.\u00a0\u00a0The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum\u2122, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment).\u00a0On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum\u2122.\u00a0\u00a0The Patent, filed with the U.S.P.T.O. is Titled \u201cMEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT\u201d.\u00a0The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.\u00a0\u00a0\u00a0<\/p>\n<p align=\"start\">On October 6, 2020, the Company announced that it has been approved to operate as a U.S. Government Vendor (CAGE CODE # 8QXV4)<\/p>\n<p align=\"start\">On October 7, 2020 the Company disclosed a Strategic Alliance with Think BIG, LLC, Social Impact Startup Founded by CJ Wallace, Son of Christopher \u201cThe Notorious B.I.G.\u201d Wallace.<\/p>\n<p align=\"start\">The Company is headquartered in New York City and operates a regional office in Barcelona, Spain.\u00a0\u00a0In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.<\/p>\n<p align=\"start\">\n        <b>DISCLAIMER &#8212; Forward-Looking Statements<\/b>\n      <\/p>\n<p align=\"start\">This press release contains certain \u201cforward-looking statements\u201d as defined by the Private Securities Litigation Reform Act of 1995 which represent management\u2019s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpects,\u201d \u201canticipates,\u201d believes, \u201chopes,\u201d \u201cbelieves,\u201d or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management\u2019s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in\u00a0\u00a0forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the \u201cRisk Factors\u201d section of Tauriga\u2019s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.<\/p>\n<p align=\"start\">\n        <b>Contact:<\/b>\n      <\/p>\n<p align=\"start\">Tauriga Sciences, Inc.<\/p>\n<p align=\"start\">555 Madison Avenue, 5th Floor<\/p>\n<p align=\"start\">New York, NY\u00a0\u00a010022<\/p>\n<p align=\"start\">Chief Executive Officer<\/p>\n<p align=\"start\">Mr. Seth M. Shaw<\/p>\n<p align=\"start\">Email:\u00a0sshaw@tauriga.com<\/p>\n<p align=\"start\">cell # (917) 796 9926<\/p>\n<p align=\"start\">Instagram: @taurigum<\/p>\n<p align=\"start\">Twitter: @SethMShaw<\/p>\n<p align=\"start\">Corp. Website:\u00a0\u00a0www.tauriga.com<\/p>\n<p align=\"start\">E-Commerce Website:\u00a0\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uyFAfMpja-oH4pFA98DsYnKXii_BiXgz2irLNjh8TBwRjsVhFhO3MydC3blwVJZRDyM9-c2WGVupvW6Vm4jEjA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.taurigum.com<\/u><\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNDk4NCMzODg5MTAyIzUwMDAzMjAzMQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/7361eb56-c964-4e40-9cc6-0b762daa5849\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>The Company\u2019s Proposed Pharma Grade Version of Tauri-Gum\u2122 is Being Developed Specifically to Target: Patients Subjected to Ongoing Chemotherapy Treatment (the \u201cIndication\u201d) NEW YORK, NY, Dec. 18, 2020 (GLOBE NEWSWIRE) &#8212; via NewMediaWire &#8212; Tauriga Sciences, Inc. (OTCQB:\u00a0TAUG) (\u201cTauriga\u201d or the \u201cCompany\u201d), a revenue generating, diversified life sciences company, with a proprietary line of functional \u201csupplement\u201d chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnologies initiatives, today announced that it has entered into a Master Services Agreement (the \u201cAgreement\u201d) with North Carolina based Clinical Strategies &amp; Tactics, Inc. (\u201cCSTI\u201d) to resume the clinical development of its proposed \u201cAnti-Nausea\u201d pharmaceutical grade version of Tauri-Gum\u2122.\u00a0CSTI will largely be focusing its efforts on the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tauriga Sciences Inc. Enters into Master Services Agreement with CSTI to Resume the Clinical Development of its Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-403013","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tauriga Sciences Inc. Enters into Master Services Agreement with CSTI to Resume the Clinical Development of its Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tauriga Sciences Inc. Enters into Master Services Agreement with CSTI to Resume the Clinical Development of its Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The Company\u2019s Proposed Pharma Grade Version of Tauri-Gum\u2122 is Being Developed Specifically to Target: Patients Subjected to Ongoing Chemotherapy Treatment (the \u201cIndication\u201d) NEW YORK, NY, Dec. 18, 2020 (GLOBE NEWSWIRE) &#8212; via NewMediaWire &#8212; Tauriga Sciences, Inc. (OTCQB:\u00a0TAUG) (\u201cTauriga\u201d or the \u201cCompany\u201d), a revenue generating, diversified life sciences company, with a proprietary line of functional \u201csupplement\u201d chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnologies initiatives, today announced that it has entered into a Master Services Agreement (the \u201cAgreement\u201d) with North Carolina based Clinical Strategies &amp; Tactics, Inc. (\u201cCSTI\u201d) to resume the clinical development of its proposed \u201cAnti-Nausea\u201d pharmaceutical grade version of Tauri-Gum\u2122.\u00a0CSTI will largely be focusing its efforts on the &hellip; Continue reading &quot;Tauriga Sciences Inc. Enters into Master Services Agreement with CSTI to Resume the Clinical Development of its Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-18T19:08:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNDk4NCMzODg5MTAyIzUwMDAzMjAzMQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tauriga Sciences Inc. Enters into Master Services Agreement with CSTI to Resume the Clinical Development of its Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum\",\"datePublished\":\"2020-12-18T19:08:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\\\/\"},\"wordCount\":1059,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNDk4NCMzODg5MTAyIzUwMDAzMjAzMQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\\\/\",\"name\":\"Tauriga Sciences Inc. Enters into Master Services Agreement with CSTI to Resume the Clinical Development of its Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNDk4NCMzODg5MTAyIzUwMDAzMjAzMQ==\",\"datePublished\":\"2020-12-18T19:08:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNDk4NCMzODg5MTAyIzUwMDAzMjAzMQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNDk4NCMzODg5MTAyIzUwMDAzMjAzMQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tauriga Sciences Inc. Enters into Master Services Agreement with CSTI to Resume the Clinical Development of its Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tauriga Sciences Inc. Enters into Master Services Agreement with CSTI to Resume the Clinical Development of its Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/","og_locale":"en_US","og_type":"article","og_title":"Tauriga Sciences Inc. Enters into Master Services Agreement with CSTI to Resume the Clinical Development of its Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum - Market Newsdesk","og_description":"The Company\u2019s Proposed Pharma Grade Version of Tauri-Gum\u2122 is Being Developed Specifically to Target: Patients Subjected to Ongoing Chemotherapy Treatment (the \u201cIndication\u201d) NEW YORK, NY, Dec. 18, 2020 (GLOBE NEWSWIRE) &#8212; via NewMediaWire &#8212; Tauriga Sciences, Inc. (OTCQB:\u00a0TAUG) (\u201cTauriga\u201d or the \u201cCompany\u201d), a revenue generating, diversified life sciences company, with a proprietary line of functional \u201csupplement\u201d chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnologies initiatives, today announced that it has entered into a Master Services Agreement (the \u201cAgreement\u201d) with North Carolina based Clinical Strategies &amp; Tactics, Inc. (\u201cCSTI\u201d) to resume the clinical development of its proposed \u201cAnti-Nausea\u201d pharmaceutical grade version of Tauri-Gum\u2122.\u00a0CSTI will largely be focusing its efforts on the &hellip; Continue reading \"Tauriga Sciences Inc. Enters into Master Services Agreement with CSTI to Resume the Clinical Development of its Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-18T19:08:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNDk4NCMzODg5MTAyIzUwMDAzMjAzMQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tauriga Sciences Inc. Enters into Master Services Agreement with CSTI to Resume the Clinical Development of its Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum","datePublished":"2020-12-18T19:08:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/"},"wordCount":1059,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNDk4NCMzODg5MTAyIzUwMDAzMjAzMQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/","name":"Tauriga Sciences Inc. Enters into Master Services Agreement with CSTI to Resume the Clinical Development of its Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNDk4NCMzODg5MTAyIzUwMDAzMjAzMQ==","datePublished":"2020-12-18T19:08:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNDk4NCMzODg5MTAyIzUwMDAzMjAzMQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNDk4NCMzODg5MTAyIzUwMDAzMjAzMQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tauriga-sciences-inc-enters-into-master-services-agreement-with-csti-to-resume-the-clinical-development-of-its-anti-nausea-pharmaceutical-grade-version-of-tauri-gum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tauriga Sciences Inc. Enters into Master Services Agreement with CSTI to Resume the Clinical Development of its Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=403013"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403013\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=403013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=403013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=403013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}